|
KMID : 1009020180160010032
|
|
Clinical Psychopharmacology and Neuroscience
2018 Volume.16 No. 1 p.32 ~ p.38
|
|
|
Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics
|
|
Paval Denis
Nemes Bogdan
Rusu Razvan L.
Dronca Eleonora
|
|
|
Abstract
|
|
|
Objective: Recent studies suggest a possible involvement of low paraoxonase 1 (PON1) enzyme activities in the association between schizophrenia, treatment with atypical antipsychotics and increased cardiovascular (CVD) risk. In the present study, we aimed at investigating the PON1 status in a group of schizophrenic patients treated with either olanzapine or other antipsychotic, as compared to a group of healthy control participants.
Methods: We assessed the arylesterase (AREase) and paraoxonase (POase) activities of PON1, as well as three common polymorphisms of PON1 gene (Q192R, L55M, ?108C＞T).
Results: We found significantly lower (?13.3%) AREase activity in schizophrenic patients, along with significantly lower (?18.2%) POase activity in olanzapine-treated patients with QQ genotype. Furthermore, we found a significant difference between groups in L55M polymorphism distribution, whereas Q192R and ?108C＞T polymorphisms distributions were similar.
Conclusion: We identified the olanzapine-treated patients with QQ genotype as having the lowest PON1 (POase) activity, providing a possible way of identifying schizophrenic patients exposed to the greatest risk of CVD.
|
|
|
KEYWORD
|
|
|
Paraoxonase 1, PON1, Polymorphism, Atypical antipsychotics, Olanzapine, Cardiovascular diseases
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|